LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Home・Elenco Azioni・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.42 0.05

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.38

Massimo

21.42

Metriche Chiave
By Trading Economics
Entrata	-1.6M -21M
Vendite	14M 54M
Margine di Profitto	-39.611
Dipendenti	178
EBITDA	-3.8M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-2.57% downside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1B 2.2B
Apertura precedente	21.37
Chiusura precedente	21.42

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

6.26 / 7.47 Supporto e resistenza

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 mar 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Principali Notizie su Eventi

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Utili

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Discorsi di Mercato

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Discorsi di Mercato

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Discorsi di Mercato

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Discorsi di Mercato

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Discorsi di Mercato

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Discorsi di Mercato

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Discorsi di Mercato

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Discorsi di Mercato

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Utili

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

-2.57% in calo

Previsioni per 12 mesi

Media 20.86 USD -2.57%

Alto 21.5 USD

Basso 17 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.